Live video webcast on Thursday, January 19th at 3:00 PM ET
A live video webcast of the presentation will be available on the Events page of the Company’s website (www.zentaris.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About
Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen™; Ghryvelin®), is the first and only
Aeterna Zentaris is dedicated to the development of therapeutic assets and has recently taken steps to establish a growing pre-clinical pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS;
For more information, please visit www.zentaris.com and connect with the Company on Twitter, LinkedIn and Facebook.
Investor Contact:
JTC Team
T (US): +1 (833) 475-8247
E: aezs@jtcir.com
![](https://ml.globenewswire.com/media/OGRhMzI4YzQtOGViYi00YjdmLTkyN2QtYjgyNjk1N2U3ZjQ2LTUwMDA3MjY3Nw==/tiny/Aeterna-Zentaris-Inc.png)
2023 GlobeNewswire, Inc., source